The Filing Desk

Valneva SE

VALN · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

VALN · Last close · November 19, 2026
$5.37

Valneva SE's revenue rose 3.0% to €175 million in fiscal 2025. Its operating margin was −47.0%, down from 7.9% a year earlier. Free cash flow was −€57 million. The diluted share count rose 15.4%.

Valneva SE Latest fiscal year ended December 31, 2025 20-F filed March 17, 2026 · 0001628280-26-018808 Updated
Revenue
€175M
3.0%
Operating margin
−47.0%
54.8 pts
Net income
−€115M
 
Free cash flow
−€57M
 
Return on capital
−34.5%
40.0 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Valneva SE is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in EUR, as it reports them: they aren't converted to US dollars. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Income statement

Revenue and net income
EUR billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
EUR billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Valneva SE lost money in fiscal 2025: a net loss of €115 million.

Diluted earnings per share
EUR per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
EUR billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
EUR billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments347286126168110
Debt incl. finance leases6599177187179
Net debt (negative means net cash)−282−188511970
Net debt to EBITDA———0.6x—
Debt to equity0.4x0.5x1.4x1.0x1.7x
Interest coverage−3.6x−6.0x−3.5x0.6x−2.0x
Current ratio1.6x1.5x1.6x2.6x2.4x
Quick ratio1.2x1.4x1.4x2.1x1.9x
EUR millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
EUR billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
EUR billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
EUR billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 94 of 91 of 9
Rule of 40−198.6%−37.5%−29.8%
Altman Z''———
Accruals ratio18.7%11.4%−13.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsFailPassFail
F-score3 of 94 of 91 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Valneva SE side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Valneva SEFY253.0%−47.0%−32.8%−34.5%—1
RegenxbioFY25104.5%−94.6%−74.2%———Compare
MacrogenicsFY25−0.3%−48.7%−55.5%———Compare
Karyopharm TherapeuticsFY250.6%−62.1%−51.6%——2Compare
Beam TherapeuticsFY25120.0%−274.6%−257.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue126110348361154170175
Revenue growth—−12.6%215.5%3.8%−57.5%10.3%3.0%
Gross profit735616037537168
Research and development3884173105607485
Operating income−1−55−61−113−8213−82
Net income−1−55−61−143−101−12−115
Diluted EPS (EUR)−0.02−0.71−0.75−1.24−0.73−0.08−0.68
Diluted shares (millions)929198116139146168
Cash flow
Cash from operations613877−245−203−67−53
Capital expenditure1019922914144
Free cash flow−5119−15−275−217−81−57
Dividends paid0000000
Share buybacks0000000
Acquisitions00001100
Stock-based compensation—614−95810
Balance sheet at fiscal year end
Cash and short-term investments64204347286126168110
Debt incl. finance leases—536599177187179
Total assets—449817621460500399
Total liabilities—372647402332319293
Shareholders' equity13577171220128181106
Margins and ratios
Gross margin58.2%50.8%46.0%10.2%34.4%41.9%38.7%
Operating margin−0.6%−50.0%−17.6%−31.4%−53.4%7.9%−47.0%
Net margin−0.6%−50.0%−17.6%−39.7%−66.0%−7.2%−66.0%
Free cash flow margin−3.9%107.7%−4.4%−76.0%−141.2%−47.8%−32.8%
Rule of 40 (growth + FCF margin)—95.1%211.1%−72.2%−198.6%−37.5%−29.8%
Return on capital————−61.4%5.5%−34.5%
Return on equity——−49.5%−73.4%−58.3%−7.9%−80.2%
Return on assets——−9.7%−19.9%−18.8%−2.5%−25.6%
Net debt to EBITDA—————0.6x—
EUR millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, EUR millions)
Source: Valneva SE's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Valneva SE.